SAN FRANCISCO, November 19, 2025 — Leads & Copy — Olema Pharmaceuticals, Inc. (Nasdaq: OLMA), a biopharmaceutical company focused on targeted therapies for breast cancer, has announced plans to commence a public offering.
The offering will involve the issuance and sale of shares of its common stock, or for certain investors, pre-funded warrants to purchase shares of its common stock, subject to market and other conditions. All securities will be offered by Olema Oncology.
Olema expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the total number of shares of common stock being offered, including shares underlying the pre-funded warrants.
TD Cowen is acting as book-running manager for the proposed offering.
The proposed offering is being made under a shelf registration statement on Form S-3, including a base prospectus, filed with the SEC on January 6, 2025, and effective as of January 15, 2025. A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC and made available for free on the SEC’s website.
Copies of the preliminary prospectus supplement and accompanying prospectus may be obtained from TD Securities (USA) LLC.
Olema Oncology is focused on therapies for breast cancer and is advancing a pipeline of novel therapies based on its knowledge of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Olema’s lead product candidate, palazestrant (OP-1250), is undergoing Phase 3 clinical trials. OP-3136, a lysine acetyltransferase 6 (KAT6) inhibitor, is in a Phase 1 clinical study. The company is headquartered in San Francisco and has operations in Cambridge, Massachusetts.
This press release does not constitute an offer to sell or a solicitation of an offer to buy securities, nor will there be any sale of these securities in any state or jurisdiction where such offer, solicitation, or sale would be unlawful prior to registration or qualification under securities laws.
Forward-looking statements in the release are subject to risks and uncertainties detailed in Olema’s reports filed with the SEC.
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com
Source: Olema Pharmaceuticals, Inc.
